Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Ciartic Move C-arm device, which facilitate enhanced efficiency with intraoperative fluoroscopic and 3D cone-beam computed tomography (CT) imaging in the OR.
Providing full motorization from the C-arm down to the wheels of the device, the Ciartic Move has self-driving capabilities that may enable better consistency with intraoperative imaging and more automated imaging workflows, according to Siemens Healthineers, the manufacturer of the Ciartic Move.
In comparison to manual adjustments with conventional C-arm devices, the recently FDA-cleared Ciartic Move device reportedly offers self-driving capabilities and storage of up to 12 procedure-specific positions with associated imaging parameters, according to Siemens Healthineers, the manufacturer of the device. (Image courtesy of Siemens Healthineers.)
Noting the device’s ability to reduce the time and workforce capacity associated with manual adjustments of conventional C-arm devices, Siemens Healthineers pointed out that the Ciartic Move device allows clinicians to store up to 12 procedure-specific positions with associated imaging parameters.
“With the FDA clearance of the Ciartic Move, Siemens Healthineers proudly introduces our first self-driving mobile C-arm, which can provide much-needed relief for overtaxed operating room teams by automating and accelerating intraoperative imaging workflows to a previously unseen degree,” said April Grandominico, vice president for surgical therapies in the Advanced Therapies business at Siemens Healthineers North America.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.